Updates are available Correction dated 2021-02-18

Article History

Received: 15 April 2020

Revised: 4 November 2020

Accepted: 6 November 2020

First Online: 3 January 2021

Change Date: 24 February 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12185-021-03091-0

Compliance with ethical standards

:

: KI reports non-financial support from Takeda during the conduct of the study; grants, personal fees or both from Takeda, Chugai, Celgene, Novartis, Abbvie, Janssen, Kyowa Kirin, Eisai, Merck, Sharp & Dohme, Astra Zeneca, FUJIFILM Toyama Chemical, Ono Pharmaceutical, Nihon Mediphysics, Dainihon Sumitomo, Bayer, HUYA Japan, Bristol Myers Squibb, Mundi Pharma, Otsuka, Daiichi Sankyo, Astellas and Asahi Kasei Pharma, outside the submitted work. MO reports personal fees from Celgene, Denovo Biopharma, Mundi Pharma, Meiji Seika Pharma, Celtrion, Verastem, Eisai and Teva Takeda, outside the submitted work. KT reports grants and personal fees from Takeda during the conduct of the study; grants, personal fees or both from Merck, Celgene, Daiichi Sankyo, HUYA Bioscience International, Mundipharma, Ono Pharmaceutical, Zenyaku Kogyo, Bristol Myers Squibb, Chugai, Eisai, Janssen, Kyowa Kirin, Meiji Seika, Solasia Pharma, Verastem, Yakult and Abbvie, outside the submitted work. KH report personal fees from Takeda, outside the submitted work. SS, MN and MH report employment with Takeda Pharmaceutical Co. Ltd. during the conduct of the study.

Free to read: This content has been made available to all.